Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.

McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, Ortmann RA, Rocha G, Rooney TP, Wehrman T, Zhang X, Zuckerman SH, Taylor PC.

Arthritis Res Ther. 2019 Aug 2;21(1):183. doi: 10.1186/s13075-019-1964-1.

2.

Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk.

Bivi N, Moore T, Rodgers G, Denning H, Shockley T, Swearingen CA, Gelfanova V, Calderon B, Peterson DA, Hodsdon ME, Siegel RW, Higgs RE, Konrad RJ.

MAbs. 2019 Jul;11(5):861-869. doi: 10.1080/19420862.2019.1612699. Epub 2019 May 17.

3.

Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay.

Konrad RJ, Higgs RE, Rodgers GH, Ming W, Qian YW, Bivi N, Mack JK, Siegel RW, Nickoloff BJ.

Sci Rep. 2019 Mar 26;9(1):5211. doi: 10.1038/s41598-019-41609-z.

4.

Interprofessional Education for Cancer Care.

McKinlay E, White K, McChesney P, Hardie C, Higgs R, Hilder J, Gallagher P.

Clin Teach. 2019 Oct;16(5):519-524. doi: 10.1111/tct.12985. Epub 2018 Dec 17.

PMID:
30560577
5.

Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice.

Martin AE, Schober DA, Nikolayev A, Tolstikov VV, Anderson WH, Higgs RE, Kuo MS, Laksmanan A, Catlow JT, Li X, Felder CC, Witkin JM.

CNS Neurol Disord Drug Targets. 2017;16(4):492-500. doi: 10.2174/1871527316666170309142646.

PMID:
28294051
6.

Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.

Hoffman RW, Merrill JT, Alarcón-Riquelme MM, Petri M, Dow ER, Nantz E, Nisenbaum LK, Schroeder KM, Komocsar WJ, Perumal NB, Linnik MD, Airey DC, Liu Y, Rocha GV, Higgs RE.

Arthritis Rheumatol. 2017 Mar;69(3):643-654. doi: 10.1002/art.39950.

7.

An innovative and highly drug-tolerant approach for detecting neutralizing antibodies directed to therapeutic antibodies.

Sloan JH, Conway RG, Pottanat TG, Troutt JS, Higgs RE, Konrad RJ, Qian YW.

Bioanalysis. 2016 Oct;8(20):2157-68. doi: 10.4155/bio-2016-0161. Epub 2016 Sep 5.

PMID:
27593891
8.

Evaluation of the Relative Performance of Drug-Induced Skeletal Muscle Injury Biomarkers in Rats.

Burch PM, Greg Hall D, Walker EG, Bracken W, Giovanelli R, Goldstein R, Higgs RE, King NM, Lane P, Sauer JM, Michna L, Muniappa N, Pritt ML, Vlasakova K, Watson DE, Wescott D, Zabka TS, Glaab WE.

Toxicol Sci. 2016 Mar;150(1):247-56. doi: 10.1093/toxsci/kfv328. Epub 2015 Dec 31.

PMID:
26721300
9.

Pain-Coping Traits of Nontraditional Women Athletes: Relevance to Optimal Treatment and Rehabilitation.

Meyers MC, Higgs R, LeUnes AD, Bourgeois AE, Laurent CM.

J Athl Train. 2015 Oct;50(10):1034-41. doi: 10.4085/1062-6050-50.8.04. Epub 2015 Sep 18.

10.

Updating the Cornell Net Carbohydrate and Protein System feed library and analyzing model sensitivity to feed inputs.

Higgs RJ, Chase LE, Ross DA, Van Amburgh ME.

J Dairy Sci. 2015 Sep;98(9):6340-60. doi: 10.3168/jds.2015-9379. Epub 2015 Jul 2.

11.

The Cornell Net Carbohydrate and Protein System: Updates to the model and evaluation of version 6.5.

Van Amburgh ME, Collao-Saenz EA, Higgs RJ, Ross DA, Recktenwald EB, Raffrenato E, Chase LE, Overton TR, Mills JK, Foskolos A.

J Dairy Sci. 2015 Sep;98(9):6361-80. doi: 10.3168/jds.2015-9378. Epub 2015 Jul 2.

12.

Food for thought: ethics case discussion as slow nourishment in a fast world.

Higgs R.

J Med Ethics. 2015 Jan;41(1):91-4. doi: 10.1136/medethics-2014-102289.

PMID:
25516945
13.

What is it to do good medical ethics? A kaleidoscope of views.

Gillon R, Higgs R.

J Med Ethics. 2015 Jan;41(1):1-4. doi: 10.1136/medethics-2014-102571. No abstract available.

PMID:
25516922
14.

A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine.

Dunne A, Mielke LA, Allen AC, Sutton CE, Higgs R, Cunningham CC, Higgins SC, Mills KH.

Mucosal Immunol. 2015 May;8(3):607-17. doi: 10.1038/mi.2014.93. Epub 2014 Oct 15.

PMID:
25315966
15.

M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine.

Witkin JM, Overshiner C, Li X, Catlow JT, Wishart GN, Schober DA, Heinz BA, Nikolayev A, Tolstikov VV, Anderson WH, Higgs RE, Kuo MS, Felder CC.

J Pharmacol Exp Ther. 2014 Nov;351(2):448-56. doi: 10.1124/jpet.114.216804. Epub 2014 Sep 3.

PMID:
25187432
16.

Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry.

Kellie JF, Higgs RE, Ryder JW, Major A, Beach TG, Adler CH, Merchant K, Knierman MD.

Sci Rep. 2014 Jul 23;4:5797. doi: 10.1038/srep05797.

17.

TRIM68 negatively regulates IFN-β production by degrading TRK fused gene, a novel driver of IFN-β downstream of anti-viral detection systems.

Wynne C, Lazzari E, Smith S, McCarthy EM, Ní Gabhann J, Kallal LE, Higgs R, Greco A, Cryan SA, Biron CA, Jefferies CA.

PLoS One. 2014 Jul 7;9(7):e101503. doi: 10.1371/journal.pone.0101503. eCollection 2014. Erratum in: PLoS One. 2015;10(2):e0117957. Greco, Angela [added].

18.

Identification of druggable cancer driver genes amplified across TCGA datasets.

Chen Y, McGee J, Chen X, Doman TN, Gong X, Zhang Y, Hamm N, Ma X, Higgs RE, Bhagwat SV, Buchanan S, Peng SB, Staschke KA, Yadav V, Yue Y, Kouros-Mehr H.

PLoS One. 2014 May 29;9(5):e98293. doi: 10.1371/journal.pone.0098293. eCollection 2014. Erratum in: PLoS One. 2014;9(9):e107646.

19.

A quantitative tool to distinguish isobaric leucine and isoleucine residues for mass spectrometry-based de novo monoclonal antibody sequencing.

Poston CN, Higgs RE, You J, Gelfanova V, Hale JE, Knierman MD, Siegel R, Gutierrez JA.

J Am Soc Mass Spectrom. 2014 Jul;25(7):1228-36. doi: 10.1007/s13361-014-0892-1. Epub 2014 May 21.

PMID:
24845350
20.

Fifty years of medical ethics: from the London Medical Group to the Institute of Medical Ethics.

Shotter E, Lloyd M, Higgs R, Boyd K.

J Med Ethics. 2013 Nov;39(11):662-6. doi: 10.1136/medethics-2013-101812. No abstract available.

PMID:
24129786
21.

Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.

Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V, Fretland A, Grime K, Hall SD, Higgs R, Plowchalk D, Riley R, Seibert E, Skordos K, Snoeys J, Venkatakrishnan K, Waterhouse T, Obach RS, Berglund EG, Zhang L, Zhao P, Reynolds KS, Huang SM.

Clin Pharmacol Ther. 2014 Feb;95(2):189-98. doi: 10.1038/clpt.2013.187. Epub 2013 Sep 18.

PMID:
24048277
22.

Pyroglutamyl apelin-13 identified as the major apelin isoform in human plasma.

Zhen EY, Higgs RE, Gutierrez JA.

Anal Biochem. 2013 Nov 1;442(1):1-9. doi: 10.1016/j.ab.2013.07.006. Epub 2013 Jul 16.

PMID:
23872001
23.

Quantitative Proteomics via High Resolution MS Quantification: Capabilities and Limitations.

Higgs RE, Butler JP, Han B, Knierman MD.

Int J Proteomics. 2013;2013:674282. doi: 10.1155/2013/674282. Epub 2013 Apr 23.

24.

Retinoic acid expression associates with enhanced IL-22 production by γδ T cells and innate lymphoid cells and attenuation of intestinal inflammation.

Mielke LA, Jones SA, Raverdeau M, Higgs R, Stefanska A, Groom JR, Misiak A, Dungan LS, Sutton CE, Streubel G, Bracken AP, Mills KH.

J Exp Med. 2013 Jun 3;210(6):1117-24. doi: 10.1084/jem.20121588. Epub 2013 May 20.

25.

The effect of starch-, fiber-, or sugar-based supplements on nitrogen utilization in grazing dairy cows.

Higgs RJ, Sheahan AJ, Mandok K, Van Amburgh ME, Roche JR.

J Dairy Sci. 2013 Jun;96(6):3857-66. doi: 10.3168/jds.2012-6117. Epub 2013 Mar 30.

26.

From ghrelin to ghrelin's O-acyl transferase.

Gutierrez JA, Willency JA, Knierman MD, Coskun T, Solenberg PJ, Perkins DR, Higgs RE, Hale JE.

Methods Enzymol. 2012;514:129-46. doi: 10.1016/B978-0-12-381272-8.00009-X.

PMID:
22975051
27.

Immunity to the respiratory pathogen Bordetella pertussis.

Higgs R, Higgins SC, Ross PJ, Mills KH.

Mucosal Immunol. 2012 Sep;5(5):485-500. doi: 10.1038/mi.2012.54. Epub 2012 Jun 20. Review.

PMID:
22718262
28.
29.

Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.

Marshall NA, Galvin KC, Corcoran AM, Boon L, Higgs R, Mills KH.

Cancer Res. 2012 Feb 1;72(3):581-91. doi: 10.1158/0008-5472.CAN-11-0307. Epub 2011 Dec 9.

30.

Enhanced interferon regulatory factor 3 binding to the interleukin-23p19 promoter correlates with enhanced interleukin-23 expression in systemic lupus erythematosus.

Smith S, Gabhann JN, Higgs R, Stacey K, Wahren-Herlenius M, Espinosa A, Totaro MG, Sica A, Ball E, Bell A, Johnston J, Browne P, O'Neill L, Kearns G, Jefferies CA.

Arthritis Rheum. 2012 May;64(5):1601-9. doi: 10.1002/art.33494.

31.

Antiviral TRIMs: friend or foe in autoimmune and autoinflammatory disease?

Jefferies C, Wynne C, Higgs R.

Nat Rev Immunol. 2011 Aug 25;11(9):617-25. doi: 10.1038/nri3043.

PMID:
21866173
32.

Public health: Ozone pollution—a link with cardiac and cerebral ischemic events?

Higgs R.

Nat Rev Cardiol. 2011 Feb;8(2):66. No abstract available.

PMID:
21348146
33.

Prevention: Supplements not cardioprotective for patients with a history of CVD.

Higgs R.

Nat Rev Cardiol. 2011 Feb;8(2):63. No abstract available.

PMID:
21348141
34.

Imaging: Fractal analysis for CHD mortality.

Higgs R.

Nat Rev Cardiol. 2011 Feb;8(2):62. No abstract available.

PMID:
21348138
35.

Rheumatoid arthritis: Immunogenicity is predictive of future treatment success in RA.

Higgs R.

Nat Rev Rheumatol. 2011 Jan;7(1):2. doi: 10.1038/nrrheum.2010.208. No abstract available.

PMID:
21260963
36.

Interventional cardiology: DES safe in large arteries.

Higgs R.

Nat Rev Cardiol. 2011 Jan;8(1):2. doi: 10.1038/nrcardio.2010.189. No abstract available.

PMID:
21218552
37.

Biliary tract: a new duct-to-duct reconstruction technique reduces biliary complications in LDLT.

Higgs R.

Nat Rev Gastroenterol Hepatol. 2010 Dec;7(12):652. doi: 10.1038/nrgastro.2010.184. No abstract available.

PMID:
21171212
38.

Osteoarthritis: Concentrated efforts to detect early OA.

Higgs R.

Nat Rev Rheumatol. 2010 Nov;6(11):616. doi: 10.1038/nrrheum.2010.165. No abstract available.

PMID:
21064241
39.

Spondyloarthropathies: Synergistic therapy protects bone in patients with AS.

Higgs R.

Nat Rev Rheumatol. 2010 Oct;6(10):556. doi: 10.1038/nrrheum.2010.149. No abstract available.

PMID:
20925145
40.

Pain: Diagnostic blocks—a pain in the back?

Higgs R.

Nat Rev Rheumatol. 2010 Oct;6(10):555. doi: 10.1038/nrrheum.2010.147. No abstract available.

PMID:
20925144
41.

Osteoarthritis: HIF-2alpha drives osteoarthritis development.

Higgs R.

Nat Rev Rheumatol. 2010 Aug;6(8):435. doi: 10.1038/nrrheum.2010.108. No abstract available.

PMID:
20704007
42.

Self protection from anti-viral responses--Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors.

Higgs R, Lazzari E, Wynne C, Ní Gabhann J, Espinosa A, Wahren-Herlenius M, Jefferies CA.

PLoS One. 2010 Jul 26;5(7):e11776. doi: 10.1371/journal.pone.0011776.

43.

Rheumatoid arthritis: Synergistic effects of growth factors drive an RA phenotype in fibroblast-like synoviocytes.

Higgs R.

Nat Rev Rheumatol. 2010 Jul;6(7):383. doi: 10.1038/nrrheum.2010.92. No abstract available.

PMID:
20614505
44.

Osteoporosis: Zoledronic acid for osteoporosis treatment--a matter of time.

Higgs R.

Nat Rev Rheumatol. 2010 Jul;6(7):382. doi: 10.1038/nrrheum.2010.96. No abstract available.

PMID:
20614504
45.

PTPRC mutation associated with response to anti-tNF therapy in rheumatoid arthritis.

Higgs R.

Nat Rev Rheumatol. 2010 Jun;6(6):311. doi: 10.1038/nrrheum.2010.69. No abstract available.

PMID:
20527672
46.

Cell-bound proteins complement current screening options in patients with SLE.

Higgs R.

Nat Rev Rheumatol. 2010 May;6(5):245. doi: 10.1038/nrrheum.2010.54. No abstract available.

PMID:
20440897
47.

Screening: A re-evaluation of KRAS mutational 'hotspots'.

Higgs R.

Nat Rev Clin Oncol. 2010 May;7(5):242. doi: 10.1038/nrclinonc.2010.54. No abstract available.

PMID:
20432530
48.

Pediatric oncology: Gene-expression profiling is prognostic in ALL cases.

Higgs R.

Nat Rev Clin Oncol. 2010 May;7(5):239. doi: 10.1038/nrclinonc.2010.58. No abstract available.

PMID:
20432522
49.

Proteomic analysis of demyelinated and remyelinating brain tissue following dietary cuprizone administration.

Werner SR, Saha JK, Broderick CL, Zhen EY, Higgs RE, Duffin KL, Smith RC.

J Mol Neurosci. 2010 Oct;42(2):210-25. doi: 10.1007/s12031-010-9354-9. Epub 2010 Apr 17.

PMID:
20401640
50.

Absence of SHIP-1 results in constitutive phosphorylation of tank-binding kinase 1 and enhanced TLR3-dependent IFN-beta production.

Gabhann JN, Higgs R, Brennan K, Thomas W, Damen JE, Ben Larbi N, Krystal G, Jefferies CA.

J Immunol. 2010 Mar 1;184(5):2314-20. doi: 10.4049/jimmunol.0902589. Epub 2010 Jan 25.

Supplemental Content

Support Center